New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
07:05 EDTFMIFoundation Medicine says new clinical data to be presented at ASCO
Foundation Medicine announced new data demonstrating that FoundationOne identified actionable genomic alterations in a broad range of pediatric cancers. These data will be presented today in a poster highlights presentation at the 2014 American Society of Clinical Oncology Annual Meeting, abstract number 10035. Fully informative genomic profiling was conducted using FoundationOne on 400 pediatric tumors from patients 21 years old or younger at the time of sample procurement. Genomic alterations were identified in a majority of 326 unselected pediatric cancer clinical cases, and 241 of these patients were found to have at least one alteration targeted by an approved therapy or investigational therapy in clinical trials. These results suggest that routine use of accurate, comprehensive genomic profiling with FoundationOne or FoundationOne Heme in pediatric patients may inform treatment options.
News For FMI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
15:10 EDTFMIFoundation Medicine to host special shareholder meeting
Subscribe for More Information
March 23, 2015
06:42 EDTFMIFoundation Medicine promotes Steven Kafka to President & COO, Jason Ryan to CFO
Subscribe for More Information
06:32 EDTFMIFoundation Medicine announces board changes in connection to Roche transaction
Foundation Medicine (FMI) announced proposed changes to its board in connection with its pending strategic collaboration with Roche (RHHBY). Under the terms of the agreement with Roche, Foundation Medicine’s board will increase to nine directors upon the closing of the transaction, including three board designees selected by Roche. The pending transaction with Roche remains subject to the satisfaction of certain closing conditions, including the successful completion of the tender offer commenced by Roche on February 2, 2015 and the approval of certain matters at the special meeting of Foundation Medicine stockholders to be held on April 2, 2015. The closing is expected to occur in the second quarter of 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use